Skip to main content
. Author manuscript; available in PMC: 2013 Jan 1.
Published in final edited form as: Biochem Pharmacol. 2011 Oct 14;83(1):149–163. doi: 10.1016/j.bcp.2011.10.007

Table 3.

Summary of the MS/MS fragmentation patterns of atRA and atRA-d5 metabolites formed by CYP26A1. The metabolites that are also oxidized to the same products when incubated separately with CYP26A1 are also listed. The five most abundant fragments that where also ≥ 10 % abundance are listed.

Metabolite rt
(min)
Parent m/z Fragment m/z
(% abundance)
Formed from
4,16-(OH)2-RA 10.4 331 257 (18), 239 (99), 201 (37),
137 (19), 119 (46)
4-OH-RA
(OH)2-RA 12.3 331 255 (69), 239 (100),
201 (17), 137 (26), 119 (49)
4-OH-RA
4-oxo-16-OH-RA 12.3 329 255 (100), 240 (19),
211 (14), 137 (16), 135 (24)
4-OH-RA and
4-oxo-RA
4,18-(OH)2-RA 13.7 331 269 (68), 251 (45), 235 (25),
137 (53), 79 (22)
4-OH-RA and
18-OH-RA
4-oxo-18-OH-RA 13.8 329 267 (75), 251 (31), 239 (22),
161 (83), 79 (100)
4-OH-RA,
4-oxo-RA and
18-OH-RA
oxo-OH-RA 14.2 329 267 (100), 229 (58),
163 (75), 161 (92), 131 (83)
4-OH-RA and
18-OH-RA
4-OH-RA 17.8 315 253 (100), 151 (19),
119 (12), 79 (13)
4-oxo-RA 18.6 313 269 (100), 254 (76),
191 (11), 163 (21), 119 (33)
4-OH-RA
16-OH-RA 19.0 315 241 (100), 119 (25)
18-OH-RA 19.5 315 271 (38), 253 (82), 241 (17),
237 (67), 151 (36)
atRA-d5 incubation
4,16-(OH)2-RA 10.4 335 261 (10), 243 (85),
204 (33), 119 (25), 79 (10)
(OH)2-RA 12.3 335 243 (100), 204 (30),
140 (13), 119 (42), 79 (13)
4-oxo-16-OH-RA 12.3 332 258 (100), 243 (11),
178 (12), 140 (20), 138 (20)
4,18-(OH)2-RA 13.6 334 272 (77), 254 (42),
238 (31), 215 (27), 138 (50)
4-OH-RA 17.7 319 257 (100), 256 (12),
154 (14)
4-oxo-RA 18.5 316 272 (100), 257 (27),
254 (82), 165 (19), 120 (34)
16-OH-RA 18.9 320 246 (100), 119 (12)
18-OH-RA 19.5 319 275 (32), 258 (14), 257 (89),
240 (36), 239 (22)